Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
Recruiting · NCT06897670 · Observational (researchers observe without assigning treatment) · Lead sponsor: Mayo Clinic
View the official record on ClinicalTrials.gov →Interventions studied
Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
What this trial is about
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- General Inclusion Criteria (across all diagnostic groups):
- 18 years and older
- Ability to provide written informed consent
- Adequate cognitive and language abilities to understand and complete study tasks, including clinical assessments and fNIRS procedures
- Confirmed clinical diagnosis of major depressive disorder, bipolar disorder, or mild cognitive impairment (MCI)
- Stable psychiatric or cognitive condition, without acute episodes requiring immediate intervention
- Specific Inclusion Criteria (for diagnostic groups):
- Healthy control
- No past or current psychiatric or cognitive disorder
- Major depressive disorder (MDD):
- Diagnosis of major depressive disorder, confirmed through clinical evaluation.
- No history of bipolar disorder or psychotic symptoms.
- Bipolar disorder:
- Diagnosis of bipolar disorder I or II, confirmed through clinical evaluation.
- Mild Cognitive Impairment (MCI):
- Pre-existing clinical diagnosis of mild cognitive impairment, supported by neuropsychological testing and/or MRI, PET scan data.
- No history of major psychiatric disorders, such as major depression, bipolar disorder or schizophrenia.
Exclusion criteria
- General Exclusion Criteria (across all diagnostic groups):
- Active primary psychotic or substance use disorders (except nicotine dependence) within the past year
- Any severe or unstable medical condition that could interfere with participation or data collection
- Any active neurological condition (including seizure disorder, traumatic brain injury, stroke) that could affect cognitive functioning or brain imaging results
- Inability to comply with study procedures, including cognitive testing, fNIRS assessment, or other assessments required by the protocol
- Pregnant women will be excluded due to potential physiological changes that could affect study outcomes
- Specific Exclusion Criteria (for diagnostic groups):
- Healthy control
- Any past or current psychiatric or cognitive disorder
- Major depressive disorder (MDD):
- Diagnosis of bipolar disorder or schizophrenia.
- Brain stimulation therapy within the past 3 months.
- Bipolar disorder:
- Diagnosis of schizophrenia or schizoaffective disorder.
- Mild Cognitive Impairment (MCI):
- Diagnosis of dementia.
- Significant cognitive impairment preventing understanding or completion of study tasks.
Where it is running
1 location listed across 1 US state.
- Mayo Clinic - Rochester, Minnesota, United States